Docket No. 277219US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND	I KADEMAKK OFFICE			
IN RE APPLICATION OF: Piergiorgio DONATI, et al.	JCO5 RJG'G PCT/PTO	19	SEP	2005
SERIAL NO: New U.S. PCT Application Based on PCT/EP04/50286	GAU:			

FILED: Herewith EXAMINER:

FOR: LIQUID GROWTH HORMONE FORMULATION AND PROCESS OF PREPARATION THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR

Applicant(s) wish to disclose the following information.

REFERENCES

- The applican(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Customer Number

22850 Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Surinder Sachar Registration No. 34.423

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 19 SEP 2005

GAU:

IN RE APPLICATION OF: Piergiorgio DONATI, et al. CT/PTO 19 SEP 200

FILED: Herewith EXAMINER:

New U.S. PCT Application Based on PCT/EP04/50286

FOR: LIQUID GROWTH HORMONE FORMULATION AND PROCESS OF PREPARATION THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

CID.

Applicant(s) wish to disclose the following information.

REFERENCES

SERIAL NO:

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Surinder Sachar Registration No. 34,423

		ATTY DOCKET NO.		SERIAL NO.				
Form PTO 1449 (Modified)		U.S. DEPARTMENT O PATENT AND TRAD	EMARK OFFICE	277219US0PCT		New U.S. PCT Application Based on PGT/ER04/50286		
		APPLICANT		10/	547/63			
LIST OF REFERENCES CITED BY APPLICANT P			Piergiorgio DONATI, et al.					
				FILING DATE		GROUP		
-				Herewith				
	U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	S SUB FILING DATE IF APPROPRIATE		
	AA	5,567,677	10/22/96	CASTENSSON, Staffan et al.				
			FO	REIGN PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO		
	AB	97/29767	08/21/97	wo			NO	
	AC	0 211 601	02/25/87	EP			NO	
	AD	93/19776	10/14/93	wo			NO	
	AE	94/03198	02/17/94	wo			NO	
	_			EP			NO	
	AE	0 131 864	01/23/85			L	1 10	
				Including Author, Title, Date, Pertinent			100 440 4000	
	AG	l .		Local Alignment Search Tool*, J. Mol. Bi				
	АН	Stephen F. ALTSCHUL et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Research, Vol. 25, No. 17, pages 3389-3402, 1997.						
	Gerald W. BECKER et al., "Isolation and Characterization of a Sulfoxide and Desamido Derivative and Biosynthetic Human							
	AJ	Growth Hormone", Biotechnology and Applied Biochemistry, Vol. 10, pages 326-337, 1988. Thomas A. BEWLY et al., "Sequence comparison of human pituitary growth hormone, human chrionic somatomammotropin,						
	AJ	and ovine pituitary growth and lactogenic hormones", Int. J. Peptide Protein Res., Vol. 4, pages 281-287, 1972.						
	AK	Vol. 4, pages 479-497, 1909.						
	AJ	John DEVEREUX et al., "A comprehensive set of sequence analysis programs for the VAX", Nucleic Acids Research, Vol. 12, No. 1, pages 387-395, 1984.						
1	AM	Arieh GERTLER et al., "Inhibition of Lactogenic Activities of Ovine Prolactin and Human Growth Hormone (hGH) by a Novel Form of a Modified Recombinant hGH* Endocrinology, Vol. 118, No. 2, pages 720-726, 1986.						
	AN	David V. GOEDDEL et al., "Direct expression in Eschenchia coli of a DNA sequence coding for human growth hormone", Nature, Vol. 281, pages 544-548, October 18, 1979.						
	AO	Laszlo GRAFF et al. "Human Somatotronin" The Journal of Biological Chemistry, Vol. 257, No. 5, pages 2356-2369, 1982.						
	AP	CRANTHAM: "Amino Acid Difference Formula to Help Explain Protein Evolution" Science, Vol. 185, pages 862-864, 1974.						
	AQ	Hansen M. HSIUNG et al., "Use of bacteriocin release protein in E. Coli for excretion of human growth hormone into the						
	AR	Culture reculum in but reculmony, your 1, pages 201-21 if, wards 1305. Karin Dayen I/D/CENSEN et al. "Pharmacokinetics of Biosynthetic and Pituitary Human Growth Hormones in Rats".						
	-	U. J. LEWIS et al., "Er	hancement of	the Hyperglycemic Activity of Human Gre	owth Horn	none by Er	zymic Modification*,	
	AS	Endocrinology, Vol. 10	1, No. 5, page	es 1587-1603, 1977.				
	AT	Chemistry, Vol. 255, No. 6, pages 2079-2007, 1976.						
	AU	1256-1265, 1979.	-	ormone: Additional members of the comp				
	AV U. J. LEWIS et al., "The 20,000-Dalton Variant of Human Growth Hormone: Location of the Amino Acid Deletions", Biochemical and Biophysical Research Communications, Vol. 92, No. 2, pages 511-516, January 29, 1980.							
	AW	Urban J. LEWIS et al., Hormone as a Result Vol. 256, No. 22, page	al., "Altered Proteolytic Cleavage of Human Growth It of Deamidation", The Journal of Biological Chemistry, Additional References sheet(s) attached					
Examiner	/Ste	ephen Gucker/			Date Co	nsidered	04/13/2009	
*Examiner: I	nitial if	reference is considered,	whether or no	ot citation is in conformance with MPEP 6	09; Draw I	ine through	h citation if not in	

Date Considered 04/13/2009

SHEET 2 QF_ 1 SERAL 5049763 ATTY DOCKET NO. U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE orm PTO 1449 New U.S. PCT Application (Modified) 277219US0PCT Based on PCT/EP04/50286 APPLICANT LIST OF REFERENCES CITED BY APPLICANT Piergiorgio DONATI, et al. FILING DATE GROUP Herewith OTHER REFERENCES (Including Author, Titte, Date, Pertinent Pages, etc.) MARTIAL et al., "Huamn Growth Hormone: Complementary DNA Cloning and Expression in Bacteria" Science, Vol. 205, pages 602-607, 1979. Judy MEINKOTH, Geoffrey WAHL: "Hybridization of Nucleic Acids Immobilized on Solid Supports", Analytical Biochemistry, Vol. 138, No. 2, pages 267-284, May 1, 1984. Jerome A. MOORE et a., "Equivalent Potency and Pharmacokinetics of Recombinant Human Growth Hormones with or without an N-Terminal Methionine", Endocrinology, Vol. 122, No. 6, pages 2920-2926.1988. William R. PEARSON: "Rapid and Sensitive Sequence Comparison with FATP and FASTA", Methods in Enzymology, Vol. 183, pages 63-98, 1990. William R. PEARSON and David J. LIPMAN: "Improved tools for biological sequence comparison", Proc. Natl. Acad. Sci., Vol. 85, pages 2444-2448, April 1988. R. PEARLMAN and T. H. NGUYEN: "Formulation Strategies for Recombinant Proteins: Human Growth Hormone and Tissue Plasminogen Activator, Therapeutic Peptides and Proteins, Formulations, Delivery and Targeting, Current Communications in Molecular Biology, pages 23-30, 1989. R. N. P. SINGH et al., "Modified Forms of Human Growth Hormone with Increased Biological Activities", Endocrinology, Vol. 94, No. 3, pages 883-891, 1974. AAD Roy G. SMITH et al., "A Nonpeptidyl Growth Hormone Secretagogue", Science, Vol. 260, pages 1640-1643, June 11, 1993. AAE SMITH and WATERMAN: "Identification of Common Molecular Subsequences", J. Mol. Biol., Vol. 147, pages 195-197, 1981. "Comparison of Biosequences", Advances in Applied Mathematics, Vol. 2, pages 482-489, 1981. AAF Ole THORLACIUS-USSING: "Zinc in the Anterior Pituitary of Rat: A Histochemical and Analytical Work", Neuroendocrinology, Vol. 45, pages 233-242, 1987. AAH AAI AAK AAI AAM

"Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ΔΔΝ

/Stephen Gucker/

Evaminer

New U.S. PCT Application Based on PCT/EP04/50286 Docket No.: 277219US0PCT

STATEMENT OF RELEVANCY

1) References AA, AB and AC have been cited in the International Search Report. Copies of these references are being submitted herewith only when not automatically provided by the International Searching Authority.
2) Reference have been cited in the corresponding Search Report. A copy of this reference is being submitted herewith.
3) References <u>AD-AAG</u> are discussed in the specification. A copy of these references is being submitted here with.
4) Reference is additional prior art known to Applicant. A copy of these references is being submitted herewith.